[ASND] Ascendis Pharma A/S

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 19.87 Change: -0.14 (-0.7%)
Ext. hours: Change: 0 (0%)

chart ASND

Refresh chart

Strongest Trends Summary For ASND

ASND is in the medium-term up 15% above S&P in 2 months and up 91% in 7 months. In the long-term up 675% in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Fundamental Ratios
Shares Outstanding EPS-2.56 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -64.77% Sales Growth - Q/Q-64.77% P/E-9.38
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-3.8% ROE-4.87% ROI
Current Ratio4.13 Quick Ratio Long Term Debt/Equity Debt Ratio0.28
Gross Margin Operating Margin-46.7% Net Profit Margin-24.89% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities47.91 M Cash From Investing Activities-410 K Cash From Operating Activities-18.4 M Gross Profit
Net Profit-5.04 M Operating Profit-7.06 M Total Assets58.67 M Total Current Assets53.16 M
Total Current Liabilities12.86 M Total Debt Total Liabilities12.86 M Total Revenue2.83 M
Technical Data
High 52 week129.99 Low 52 week55.16 Last close122.37 Last change-0.42%
RSI64.33 Average true range4.3 Beta0.85 Volume16.12 K
Simple moving average 20 days4.08% Simple moving average 50 days3.33% Simple moving average 200 days51.59%
Performance Data
Performance Week0.83% Performance Month14.25% Performance Quart66.63% Performance Half100.61%
Performance Year79.96% Performance Year-to-date95.32% Volatility daily2.18% Volatility weekly4.87%
Volatility monthly9.97% Volatility yearly34.55% Relative Volume225.05% Average Volume420.32 K
New High New Low

News

2019-06-19 08:30:00 | Ascendis Pharma A/S Announces R&D Day on June 26 to Review Endocrinology Rare Disease Pipeline and Introduce Oncology Programs

2019-06-10 10:10:04 | Hedge Funds Have Never Been This Bullish On Ascendis Pharma A/S ASND

2019-05-31 02:02:33 | Edited Transcript of ASND earnings conference call or presentation 30-May-19 8:30pm GMT

2019-05-30 16:02:00 | Ascendis Pharma A/S Reports First Quarter 2019 Financial Results

2019-05-30 14:30:00 | Ascendis Pharma A/S to Host Earnings Call

2019-05-20 07:30:00 | Ascendis Pharma A/S Announces Preliminary Data from Single Arm Phase 3 fliGHt Trial Demonstrated TransCon™ hGH was Safe and Well-Tolerated in Pediatric Subjects Previously Treated with Daily Growth Hormone

2019-05-16 08:00:00 | Ascendis Pharma A/S Announces First Quarter 2019 Financial Results and Business Update Conference Call on May 30

2019-05-07 16:02:00 | Ascendis Pharma A/S Announces Participation in the Bank of America Merrill Lynch 2019 Healthcare Conference

2019-05-07 12:43:29 | Wyndham Hotels & Resorts, Inc. WH: 2019 Sohn Conference New York Recap

2019-05-06 11:09:23 | What You Must Know About Ascendis Pharma A/S's NASDAQ:ASND Financial Health

2019-04-29 09:28:38 | Did Hedge Funds Drop The Ball On Ascendis Pharma A/S ASND ?

2019-04-27 08:40:09 | Glenview Capital Management’s Stock Pitches At 2018 Sohn Conference

2019-04-24 17:26:39 | Ascendis Pharma A/S Announces Presentations Related to Rare Disease Endocrinology Pipeline at Upcoming Medical Conferences

2019-04-23 08:59:36 | Joseph Jolson’s Harvest Capital Strategies’ Return, AUM, and Holdings

2019-04-20 12:25:36 | Best Stock Pick From The 2018 Sohn Conference Part II

2019-04-11 01:11:07 | What Happened With Light Street’s Glen Kacher’s Best Idea at 2018 Sohn Conference?

2019-04-08 13:06:03 | Mangrove Partners’ Nathaniel August’s Best Idea At 2018 Sohn Conference

2019-04-07 23:59:13 | Sarissa Capital Management Hires New President

2019-04-04 01:14:21 | Ascendis Pharma A/S ASND Q4 2018 Earnings Conference Call Transcript

2019-04-03 23:49:22 | Edited Transcript of ASND earnings conference call or presentation 3-Apr-19 8:30pm GMT

2019-04-03 16:01:00 | Ascendis Pharma A/S Reports Full Year 2018 Financial Results

2019-04-03 14:30:00 | Ascendis Pharma A/S Sponsored ADR to Host Earnings Call

2019-03-27 17:00:00 | Ascendis Pharma A/S Announces Year-End 2018 Financial Results and Business Update Conference Call on April 3

2019-03-25 14:45:06 | Ascendis Pivotal Growth Hormone Deficiency Study Data Positive

2019-03-25 14:00:00 | Ascendis Pharma Announces Results of Study at ENDO 2019 Evaluating Impact of Hypoparathyroidism on Patient Quality-of-Life

2019-03-24 12:45:00 | Ascendis Pharma Announces Phase 3 heiGHt Trial Demonstrated Superior Efficacy and Comparable Safety and Tolerability of TransCon™ hGH to a Daily Growth Hormone

2019-03-14 13:08:12 | ValueAct Capital’s CBRE Recommendation Delivers 150% Gain

2019-03-12 10:56:02 | What Makes Ascendis Pharma A/S ASND a New Buy Stock

2019-03-07 07:10:00 | Report: Exploring Fundamental Drivers Behind Manulife Financial, Fidelity National Financial, Heritage-Crystal Clean, Ericsson, Ascendis Pharma A/S, and Astec Industries — New Horizons, Emerging Trends, and Upcoming Developments

2019-03-06 14:31:13 | Shareholders Are Raving About How The Ascendis Pharma Share Price Increased 602%

2019-03-06 10:00:00 | Under the Radar Cannabis Stock-THC Therapeutics, Inc.

2019-03-06 04:05:45 | Ascendis Pharma Prices 4.166M ADS Offering @$122/ADS

2019-03-05 20:07:46 | Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

2019-03-05 09:43:02 | Company News For Mar 5, 2019

2019-03-04 16:01:00 | Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

2019-03-04 13:24:20 | Why Ascendis Pharma Is Soaring Today

2019-03-04 06:30:00 | Ascendis Pharma Announces Once-weekly TransCon™ Growth Hormone Demonstrated Superiority on Primary Endpoint Compared to a Daily Growth Hormone in Phase 3 heiGHt Trial for Pediatric Growth Hormone Deficiency

2019-02-28 20:20:45 | Ascendis Pharma Announces Orphan Drug Designation Granted for TransCon CNP as Treatment for Achondroplasia

2019-02-28 07:45:00 | Recent Analysis Shows Intel, Gilead Sciences, Amdocs, Ascendis Pharma A/S, Hill-Rom, and Ingevity Market Influences — Renewed Outlook, Key Drivers of Growth

2019-02-13 09:53:02 | Ascendis Pharma Files IND for Hypoparathyroidism Candidate

2019-02-11 17:27:08 | Ascendis Pharma Initiates Global Phase 2 Trial for TransCon PTH in Adult Subjects with Hypoparathyroidism

2019-01-25 09:18:02 | All You Need to Know About Ascendis Pharma A/S ASND Rating Upgrade to Buy

2019-01-07 09:00:00 | Ascendis Pharma A/S Introduces Vision 3x3: A Strategic Roadmap Through 2025 to Achieve Sustainable Growth Using Multiple Approaches

2018-12-21 16:01:00 | Ascendis Pharma A/S Announces Participation in 37th Annual J.P. Morgan Healthcare Conference

2018-12-12 02:57:10 | Should You Buy Ascendis Pharma A/S ASND?

2018-11-29 02:11:50 | Edited Transcript of ASND earnings conference call or presentation 28-Nov-18 9:30pm GMT

2018-11-28 23:03:09 | Ascendis Pharma A/S ASND Q3 2018 Earnings Conference Call Transcript

2018-11-28 16:05:00 | Ascendis Pharma A/S Reports Third Quarter 2018 Financial Results

2018-11-28 16:01:00 | Ascendis Pharma A/S Announces Positive Preliminary Phase 1 Data for TransCon CNP

2018-11-14 16:15:00 | Ascendis Pharma A/S Announces Third Quarter 2018 Financial Results and Business Update Conference Call on November 28